title: Hepatitis B in transplantation.
abstract: Hepatitis B has been a major challenge within the field of transplantation over the past few decades. Due to aggressive recurrence post-transplant, patients with hepatitis B have been excluded from the benefits of both solid organ and bone marrow transplants. Progress has been made, however, through an improved understanding of the biology of hepatitis B and the development of new antiviral strategies that can reliably suppress the virus. Patients with hepatitis B are now candidates for transplantation in an increasing number of circumstances. Careful pre-transplant evaluation is mandatory, together with a tailored antiviral regimen depending on the replicative status of the virus and the organ being transplanted. Minimizing steroid dose following transplantation is an important part of the strategy to reduce the risk of viral reactivation. Lamivudine has been an important development and it has assumed an increasing role in the management of these patients. As additional antivirals are developed, increasingly effective drug combinations will prevent viral recurrence as well as the emergence of drug-resistant mutants, which plagues the use of single agents. It is a rapidly evolving field and there is every reason for continued optimism.
authors: Alberta Liver Transplant Program, Department of Medicine, University of Alberta, Division of Gastroenterology, Edmonton, Alberta, Canada. vince.bain@ualberta.ca
authors: V G
authors: VG
authors: Bain
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000009:adverse effects* / Q000276:immunology; D006509:Hepatitis B / Q000175:diagnosis / Q000503:physiopathology* / Q000517:prevention & control; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D016377:Organ Transplantation; D011183:Postoperative Complications / Q000821:virology*; D014019:Tissue Donors; D014181:Transplantation Immunology
chemical_list: D000998:Antiviral Agents